Multiple myeloma accounts for about 1% of all types of human cancer and 13% of all haematological malignancies. Much molecular study currently is being undertaken on the disease, as the following selection of articles illustrates.
Fluorescence in situ hybridization (FISH) in multiple myeloma.
Tian E. Methods Mol Biol 2018; 1792: 55–69.
The application of fluorescence in situ hybridisation (FISH) technology in the diagnosis and molecular classification of cancer-risk has become an essential tool in the progress of personalised therapy. In multiple myeloma, the precise FISH detection of numerical and structural genetic aberrations can be carried out on metaphase chromosome spreads, interphase nuclei, and formalin-fixed, paraffin wax-embedded (FFPE) tissues. To dissect highly complex cancer genomes, a broad variety of novel DNA probes, which outpace supplies from commercial resources on the market, are also crucial to advanced translational research. In this article, the author provides the protocols for the creation of custom-made DNA probes and for conducting hybridisations on various targeted cells and tissues.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.